Popliteal Pterygium Syndrome 1 (PPS1)

Popliteal pterygium syndrome 1 (PPS1) is a rare, inherited condition that affects how parts of the face, skin, limbs, and genitals form before birth. Children are often born with a web of tight skin and tissue behind the knee (a “popliteal pterygium”) that can hold the knee in a bent position. Many also have a cleft lip and/or cleft palate, small pits or little mounds on the lower lip, and changes in fingers, toes, nails, and genitals. The condition is usually autosomal dominant, which means one changed copy of a gene can cause the syndrome. In PPS1, the main gene is IRF6, a transcription-factor gene important for normal development of the lips, palate, skin, and genitals. Different mutations in the same gene can also cause Van der Woude syndrome (VWS); PPS generally has all the features of VWS plus the characteristic popliteal web and some limb or genital features. monarchinitiative.org+3MedlinePlus+3NCBI+3

Popliteal pterygium syndrome 1 (PPS1) is a rare, autosomal-dominant genetic condition most often caused by a change (variant) in a gene called IRF6. People with PPS1 can have webbing behind the knee (a “pterygium” that restricts knee straightening), cleft lip and/or cleft palate, pits on the lower lip, and differences in the hands, feet, skin, nails, and genitals. PPS1 belongs to a spectrum of IRF6-related disorders that ranges from Van der Woude syndrome (milder) to PPS1 (more severe). Because PPS1 starts during early development, treatment focuses on timely surgery, therapy, dental and speech care, and life-long team follow-up rather than any single medicine. NCBI+2MedlinePlus+2

Why IRF6 matters: IRF6 is a transcription factor that helps guide how skin and facial tissues form in the embryo. When IRF6 doesn’t work properly, the “periderm” (a temporary protective skin layer) and other early tissues don’t separate or fuse normally, producing features like lip pits, oral clefts, and skin webs. This biology explains why PPS1 affects the face, skin, mouth, and joints. NCBI+2MedlinePlus+2

How PPS1 differs from other popliteal pterygium syndromes: PPS1 is usually autosomal dominant (one changed copy of IRF6 is enough). There are rarer, often more severe autosomal recessive forms (sometimes called Bartsocas–Papas syndrome) caused by RIPK4 or CHUK (IKKA)—these are not PPS1, but they help explain the biological pathway linked to skin and cleft development. Knowing the exact gene helps with counseling and surgical planning. PubMed+2PubMed+2

Other names

Doctors and databases may use slightly different labels for the same condition. Common synonyms include:

• Autosomal-dominant popliteal pterygium syndrome

• IRF6-related popliteal pterygium syndrome

• PPS (type 1) / PPS1
  These names all point to the dominant, IRF6-related form. Note that there are recessive popliteal-pterygium conditions caused by other genes (for example, RIPK4), often called Bartsocas–Papas spectrum; those are not PPS1 but are part of the broader “popliteal pterygium syndromes.” Orpha+2Orpha+2

Types

It helps to separate PPS1 from related but distinct disorders:

1. PPS1 (autosomal dominant, IRF6) – the classic form discussed in this article: cleft lip/palate, lower-lip pits, popliteal pterygium, genital differences, and digit/nail changes. NCBI

2. Recessive PPS / Bartsocas–Papas spectrum (often RIPK4) – usually more severe, sometimes lethal in the newborn period, with extensive webbing and ectodermal findings; inheritance and gene are different. PMC+1

3. Broader “PPS” umbrella usage – some sources group multiple entities under “popliteal pterygium syndromes”; PPS1 is the IRF6, autosomal-dominant subtype within that group. Orpha

Causes

Because PPS1 is genetic, “causes” here means the different genetic/mechanistic ways PPS1 can arise, plus well-recognized modifiers and clinical genetics factors that influence who is affected and how.

1. Pathogenic variants in IRF6 – single “spelling” changes that alter the IRF6 protein and disrupt normal facial, skin, and genital development. PubMed

2. DNA-binding domain mutations – many PPS1 mutations cluster in the IRF6 DNA-binding region, disturbing its ability to switch on target genes. Wikipedia

3. Dominant-negative effects – some mutant IRF6 proteins interfere with the normal copy, worsening the phenotype. PubMed

4. Haploinsufficiency – having only one working IRF6 copy may be inadequate for normal development, contributing to clefting features. PubMed

5. Autosomal-dominant inheritance – a parent with PPS1 can pass the variant to a child with a 50% chance in each pregnancy. NCBI

6. De novo mutations – a new IRF6 change can appear in the child even when neither parent is affected. Nature

7. Parental germline mosaicism – a parent may carry the mutation in a portion of their egg or sperm cells only, leading to recurrence in siblings despite normal parental testing. (Documented across IRF6-related disorders.) NCBI

8. Allelic heterogeneity with VWS – different IRF6 changes can produce VWS or PPS; PPS-associated variants are enriched in functional domains tied to pterygium and limb/genital findings. GIM Journal

9. Gene-expression disruption during palatal fusion – IRF6 is highly expressed along the edges where the palate fuses; disruption raises cleft risk. PubMed

10. Abnormal epidermal/keratinocyte differentiation – IRF6 influences skin development, helping explain lip pits and webs. PubMed

11. Embryonic soft-tissue patterning errors behind the knee – altered signaling and scarring can leave a permanent web (“pterygium”). (Mechanistic inference supported by phenotype and IRF6 biology.) NCBI

12. Modifier genes – background variation in other developmental genes likely modifies severity (well-recognized concept in IRF6 disorders). NCBI

13. Penetrance and variable expressivity – the same mutation can look different between family members, from mild lip pits to full PPS. NCBI

14. Advanced paternal age (de novo risk) – some clinical resources note an association between sporadic PPS and older paternal age, a general pattern for de novo dominant conditions. Limb Lengthening Center

15. Small IRF6 deletions/duplications – less common copy-number changes can affect the gene’s function similar to point variants. (Recognized in IRF6 testing algorithms.) NCBI

16. Nonpenetrant carriers in families – a parent may carry the change but show few signs (e.g., subtle pits), complicating family history. NCBI

17. Epigenetic influences on IRF6 pathways – changes in gene regulation can modify expression levels and features (mechanism discussed in IRF6 literature). GIM Journal

18. Environmental contributors to cleft severity (general) – while the IRF6 variant is primary, general cleft risk factors (e.g., maternal nutrition, smoking) can influence expression and care needs; they do not cause PPS without the IRF6 variant. (General cleft background within IRF6-related disorders.) NCBI

19. Misclassification with recessive PPS – different genes (e.g., RIPK4) can mimic the phenotype but are separate causes; correct gene testing clarifies true PPS1. PMC

20. Stochastic developmental variation – normal biological variability during embryogenesis helps explain side-to-side differences and incomplete features, even with the same variant. (Well-accepted concept in developmental genetics; discussed in IRF6-related disorder variability.) NCBI

Common symptoms and signs

1. Popliteal pterygium (web behind the knee). Tight skin and fibrous tissue limit knee straightening and can shorten muscles and nerves if not treated early. NCBI

2. Cleft lip and/or cleft palate. An opening in the lip and/or the roof of the mouth that affects feeding, speech, and ear health; common in PPS1. MedlinePlus

3. Lower-lip pits or small tissue mounds. Tiny depressions or bumps in the lower lip linked to minor salivary glands; classic for IRF6 disorders. MedlinePlus

4. Syndactyly or toe/finger webbing. Fusion or webbing of digits; nails can be small or misshapen. NCBI

5. Nail abnormalities. Nails may be thin, small, or ridged, reflecting ectodermal involvement. NCBI

6. Genital differences in males. Bifid (split) scrotum and undescended testes are reported. NCBI

7. Genital differences in females. Underdeveloped labia majora and other variations can occur. NCBI

8. Oral adhesions (syngnathia). Thin bands can partly fuse the jaws, limiting mouth opening in some cases. NCBI

9. Skin folds or pterygia at other sites. Webs can appear elsewhere (e.g., axilla), though the popliteal web is defining. NCBI

10. Dental anomalies. Missing teeth or enamel differences may be seen, similar to VWS. NCBI

11. Feeding and speech issues (from cleft). Babies may need specialized bottles; later, speech therapy and ear care are common. MedlinePlus

12. Ear problems/otitis media with effusion. Fluid and infections are common in children with cleft palates and may affect hearing. MedlinePlus

13. Facial differences. Features vary, but the combination of lip pits, cleft, and skin webs points to the diagnosis. NCBI

14. Limited knee extension and gait changes. The web holds the knee flexed; walking can be awkward without release. PMC

15. Cosmetic and psychosocial impact. Visible differences can affect confidence and social interaction; counseling often helps. (General supportive care principle in cleft and congenital limb differences.) National Organization for Rare Disorders

---

Diagnostic tests

A) Physical examination

1. Full newborn and pediatric exam. A careful head-to-toe check looks for lip pits, cleft, webs, nail changes, digit webbing, and genital differences—the pattern raises suspicion for PPS1. MedlinePlus+1

2. Focused knee examination. The clinician measures how much the knee can straighten and checks skin tightness and neurovascular status around the popliteal web. PMC

3. Oral cavity inspection. The provider looks for cleft palate, lip pits, small tissue mounds, and any oral adhesions (syngnathia). MedlinePlus+1

4. Hand/foot and nail assessment. Counting digits, checking for webbing, and reviewing nail shape helps document ectodermal involvement. NCBI

5. Genital exam. In males, exam checks for bifid scrotum and undescended testes; in females, labial development is assessed. NCBI

B) Manual / functional tests

6. Range-of-motion (ROM) testing. Gentle goniometer measurements document knee flexion contracture and guide therapy or surgery timing. PMC

7. Feeding assessment. For babies with cleft palate, a feeding specialist evaluates suck, swallow, and need for special bottles to ensure safe nutrition. MedlinePlus

8. Speech-language evaluation. As the child grows, speech therapists check resonance and articulation affected by cleft palate and plan therapy. MedlinePlus

9. Hearing screening (newborn and follow-up). Simple bedside or clinic hearing tests (OAE/ABR in infants; audiology later) catch middle-ear fluid and hearing loss common in cleft palate. MedlinePlus

C) Laboratory / genetic / pathology tests

10. IRF6 gene sequencing. This is the key test; it reads the IRF6 code to find a variant that explains PPS1. Positive results confirm the diagnosis and guide family counseling. NCBI

11. Deletion/duplication analysis for IRF6. If sequencing is negative, copy-number testing looks for small missing or extra pieces affecting IRF6. NCBI

12. Targeted variant testing in families. When a familial IRF6 change is known, relatives can be tested quickly for that exact change. NCBI

13. Multigene cleft panels (with IRF6 included). Broader panels are useful when the presentation is atypical or when you must rule out other cleft/pterygium genes. NCBI

14. Prenatal genetic testing (CVS/amniocentesis) if familial variant known. Testing fetal DNA for the known IRF6 change supports planning and delivery at a cleft-experienced center. NCBI

15. Research-level functional assays (rarely used clinically). Laboratories sometimes study how a specific IRF6 variant changes protein function; this helps classify uncertain variants. GIM Journal

D) Electrodiagnostic tests

16. Nerve-conduction studies (selected cases). If severe contracture suggests nerve stretch or entrapment around the knee, electrodiagnostic testing can check signal speed and integrity; this is not routine in uncomplicated PPS1. (General orthopedic principle; used selectively.) PMC

17. Electromyography (EMG) (selected cases). If muscle imbalance or denervation is suspected due to long-standing flexion, EMG may help plan surgery or therapy; again, this is case-by-case. (Selective use in contracture evaluation.) PMC

E) Imaging tests

18. Knee and lower-limb ultrasound or MRI. Imaging shows how far the web extends, involvement of fascia and neurovascular structures, and helps surgeons plan safe release. PMC

19. Orthopedic radiographs of knees/feet. X-rays evaluate joint position, bone alignment, and any bony fusions that might affect surgery or therapy. PMC

20. Prenatal ultrasound (and, if needed, fetal MRI). In families with a known variant—or in severe cases—prenatal scans may detect clefts or limb positioning concerns and aid delivery planning. NCBI

Non-pharmacological treatments (therapies and others)

1. Cleft team care: A coordinated ACPA-approved cleft/craniofacial team (surgery, dental, speech, audiology, nursing, psychology) sequences care from birth through adulthood. Purpose: improve outcomes and reduce delays. Mechanism: integrated, guideline-based planning and follow-up. ACPA+1

2. Feeding support and lactation counseling: Early guidance on positioning and specialized, squeezable bottles helps babies grow until repair. Purpose: prevent dehydration and poor weight gain. Mechanism: compensates for ineffective oral seal and nasal regurgitation. Cochrane

3. Nasoalveolar molding (NAM): Gentle plates and nasal stents reshape gums and nose in the first months. Purpose: reduce cleft width and improve nasal symmetry before surgery. Mechanism: continuous low-force molding of cartilage and alveolus. PubMed+1

4. Speech-language therapy: Targets resonance and articulation after palate repair. Purpose: intelligible speech. Mechanism: teach correct placement/airflow; treat compensatory patterns. PMC+1

5. Ear/hearing management: Regular audiology, possible hearing aids; (surgical tubes are separate). Purpose: preserve language development. Mechanism: address conductive loss from middle-ear fluid. ASHA

6. Popliteal web stretching & splinting (pre/post-op): Gentle range-of-motion and splints. Purpose: maintain extension gains. Mechanism: controlled tissue lengthening and scar remodeling. Lippincott Journals

7. Physiotherapy-guided gait training: Re-educate gait after releases. Purpose: improve walking and prevent compensations. Mechanism: strengthening, balance, motor patterning. MDPI

8. Scar care (massage/silicone sheets) after lip/palate/knee surgery. Purpose: softer, flatter scars; reduce contracture. Mechanism: hydration and mechanical remodeling of collagen. ACPA

9. Orthodontics and dentofacial orthopedics: Phase-wise expansion, alignment, alveolar bone graft planning. Purpose: functional bite and esthetics. Mechanism: tooth movement and bony support for the dental arch. ACPA

10. Psychosocial counseling for child/parents. Purpose: resilience and coping with procedures/appearance changes. Mechanism: CBT/supportive therapy and peer support networks. ACPA

11. Educational support & speech accommodations in school. Purpose: communication access and confidence. Mechanism: individualized education plans and classroom strategies. ACPA

12. Oral hygiene coaching around repairs. Purpose: reduce infections and support wound healing. Mechanism: brushing, rinses, dental home. AAPD

13. Nutritional guidance for growth. Purpose: adequate calories/protein before and after surgery. Mechanism: dietitian-led plans, safe textures after palate repair. ACPA

14. Airway positioning & safe sleep strategies in infants with wide clefts. Purpose: reduce obstruction events. Mechanism: positional support and monitoring per team guidance. ACPA

15. Desensitization and play therapy around medical care. Purpose: reduce procedure anxiety and improve cooperation. Mechanism: gradual exposure, family coaching. ACPA

16. Occupational therapy for fine-motor adaptation if hand/foot anomalies limit daily tasks. Purpose: independence in self-care/school activities. Mechanism: task practice and adaptive tools. ACPA

17. Social work & care coordination. Purpose: connect families with services, travel help, and financial support. Mechanism: navigation across multi-stage care. ACPA

18. Pre-op anesthesia assessment tailored to cleft/airway and knee webbing. Purpose: safe anesthesia. Mechanism: risk stratification, airway planning. ACPA

19. Post-op rehab protocols (timed ROM, wound checks) after web releases. Purpose: maintain function and prevent re-contracture. Mechanism: structured follow-up. Lippincott Journals

20. Genetic counseling for families. Purpose: explain inheritance and recurrence risk. Mechanism: IRF6 testing review and family planning discussion. NCBI

---

Drug treatments

These medicines are not approved to treat PPS1; they are used for pain control, nausea prevention, oral wound care, or treating infections related to surgeries or dental/ENT issues. Doses below illustrate label-based information; clinicians individualize for age, weight, renal function, and surgery type.

1. Acetaminophen (paracetamol): For fever/pain after surgeries. Class: analgesic/antipyretic. Label dosing examples: adult dosing per label; pediatric dosing weight-based. Timing: post-op and short-term. Purpose: reduce pain/fever without NSAID GI effects. Mechanism: central COX inhibition. Key safety: hepatotoxicity if exceeding max total daily dose. FDA Access Data+1

2. Ibuprofen: For mild–moderate pain/fever if not contraindicated. Class: NSAID. Dose/timing: per label; use smallest effective dose. Purpose: anti-inflammatory analgesia. Mechanism: COX-1/COX-2 inhibition. Key safety: GI, renal, CV warnings; avoid around certain surgeries per clinician. FDA Access Data+1

3. Amoxicillin: For dental/ENT infections when indicated. Class: penicillin-class antibiotic. Dose/timing: label-guided; renal adjustment if severe impairment. Purpose: treat susceptible bacteria. Mechanism: cell wall synthesis inhibition. Safety: allergy, diarrhea. FDA Access Data

4. Amoxicillin-clavulanate (Augmentin): Broader coverage if β-lactamase producers suspected (e.g., otitis media/sinusitis per clinician). Class: penicillin + β-lactamase inhibitor. Dose/timing: per specific product labels (including pediatric ES-600). Safety: hypersensitivity, cholestatic jaundice risk. FDA Access Data+2FDA Access Data+2

5. Cephalexin (Keflex): Alternative for skin/soft-tissue or dental infections when appropriate. Class: 1st-gen cephalosporin. Dose/timing: per label. Safety: penicillin cross-reactivity, GI upset. FDA Access Data

6. Clindamycin: For penicillin-allergic patients or anaerobe-predominant infections per clinician. Class: lincosamide. Dose/timing: per oral or IV label. Safety: C. difficile-associated diarrhea warning. FDA Access Data+1

7. Ondansetron (Zofran): Prevent/treat post-op nausea/vomiting. Class: 5-HT3 antagonist. Dose/timing: oral/IV label dosing. Safety: QT prolongation risk, contraindicated with apomorphine. FDA Access Data+1

8. Chlorhexidine 0.12% oral rinse: Short-term oral hygiene adjunct after oral surgery (if prescribed). Class: antiseptic mouthwash. Dose/timing: per label instructions. Safety: tooth staining, taste disturbance. FDA Access Data

9. Topical mupirocin (Bactroban): For limited superficial skin infection around minor wounds per clinician. Class: topical antibiotic. Dose/timing: label-directed. Safety: hypersensitivity. FDA Access Data

10. Dexamethasone (injection): Used intra-/post-operatively for antiemesis and swelling control when indicated. Class: corticosteroid. Dose/timing: per label; individualized. Safety: hyperglycemia, infection risk. FDA Access Data

11. Acetaminophen-ibuprofen fixed dose (e.g., Combogesic): Analgesic synergy under label guidance. Class: non-opioid combo. Safety: respect both components’ dose limits. FDA Access Data

12. Amoxicillin ER (Moxatag): Specific pharyngitis indication; included here to show amoxicillin label range when clinicians select formulations for dental/ENT overlap—always indication-guided. Safety: penicillin allergy. FDA Access Data

13. Peri-op saline/antiseptic irrigation (device/solution labeling varies): Surgeon-directed adjunct for wound hygiene. Purpose/mechanism: reduce bioburden. Safety: product-specific. (Use per institutional protocols.) ACPA

14. Topical oral analgesic regimens (local protocols): Short, targeted use to ease mucosal discomfort post-repair, as directed. Note: product selection per age and label. ACPA

15. Antibiotic choices for acute otitis media (when indicated): Examples include amoxicillin-clavulanate ES-600 per label pediatric dosing. Purpose: treat middle-ear infection to protect hearing/speech. Safety: usual β-lactam cautions. FDA Access Data

16. Peri-op analgesic ladder emphasizing non-opioids first; if opioids are used, they follow strict surgical protocols and labels (not listed here to avoid over-generalization). Purpose: adequate pain control with minimal harm. Mechanism: multimodal analgesia. FDA Access Data

17. Bowel regimen when opioids are used: Label-directed choices (e.g., PEG-electrolyte solutions are for colon prep; clinicians use appropriate laxatives separately). Note: choose pediatric-appropriate agents per label. FDA Access Data

18. Antibiotic stewardship: Use only when infection is proven or strongly suspected, per label statements, to avoid resistance. Mechanism: targeted therapy. FDA Access Data

19. Peridex-aided hygiene around orthodontic appliances if prescribed for short courses. Purpose: plaque control. Mechanism: antiseptic film. Safety: discoloration. FDA Access Data

20. Anti-emetic strategy anchored on ondansetron with anesthetic team protocols to reduce post-op vomiting, improving feeding/hydration. Safety: avoid drug interactions/QT risk. FDA Access Data

---

Dietary molecular supplements

1. Folic acid (periconception) lowers overall risk of neural-tube defects in the population; included here for family planning context rather than PPS1 therapy. Typical recommendation: 400 mcg/day for those who can become pregnant. Function: 1-carbon metabolism, DNA synthesis. Mechanism: supports neural tube closure early in pregnancy. CDC+1

2. Vitamin D: supports bone/immune health; useful when activity is limited post-op or outdoors time is low; dosage per clinician. Mechanism: calcium/phosphate homeostasis. (General guidance; not PPS-specific.) ACPA

3. Calcium: bone health during growth/rehab; dose individualized by age/diet. Mechanism: skeletal mineralization. ACPA

4. Iron (if deficient): supports growth and healing; dose guided by labs to avoid overload. Mechanism: hemoglobin synthesis. ACPA

5. Zinc: cofactor in wound repair; only if diet is poor or deficiency documented. Mechanism: epithelial and immune enzyme function. ACPA

6. Omega-3 fatty acids: general anti-inflammatory support; food-first approach (fish) preferred; supplement per clinician. Mechanism: eicosanoid modulation. ACPA

7. Protein-rich nutrition (whey or equivalent if intake is low): supports wound healing. Mechanism: provides amino acids for collagen and muscle. ACPA

8. B-complex if dietary insufficiency is suspected. Mechanism: coenzymes for energy and tissue repair. ACPA

9. Probiotics during necessary antibiotics may reduce antibiotic-associated diarrhea; product and dosing vary; clinician-guided. Mechanism: microbiome support. ACPA

10. Multivitamin bridging poor intake around surgeries; avoid megadoses. Mechanism: broad micronutrient coverage. ACPA

---

Immunity booster / regenerative / stem-cell drugs

No FDA-approved stem-cell, exosome, or “regenerative” drugs exist for PPS1. The FDA warns consumers that most marketed “regenerative” interventions are unapproved, and many are unsafe or misleading. Bone-marrow/cord-blood products have specific hematologic indications, not PPS1. If you see clinics promising stem-cell cures for congenital syndromes or orthopedic contracts, be cautious and consult your cleft/craniofacial team. U.S. Food and Drug Administration+1

1. Autologous stem-cell injections (marketing claims, not approved for PPS1): Not FDA-approved for congenital webs or clefts. Risks include infection, inflammation, and wasted cost. Function/Mechanism (claimed): tissue regeneration; Reality: unsupported for PPS1. U.S. Food and Drug Administration

2. Exosome products (marketing claims): FDA states there are no approved exosome products. Function/Mechanism (claimed): cell signaling to regenerate tissue; Reality: unapproved/unsafe outside trials. U.S. Food and Drug Administration

3. Perinatal tissue “stem-cell” vials sold direct-to-consumer: the FDA has pursued enforcement; harms reported in literature and media. Use: none for PPS1. Mechanism (claimed): regenerative; Reality: unapproved. PMC+1

4. Orthopedic stem-cell offerings for contractures: not FDA-approved; legal status varies by state and remains controversial; not a treatment for PPS1 webs. Mechanism (claimed): cartilage/tendon repair; Reality: unproven. CalMatters

5. Umbilical products promoted for wound healing: warning letters and safety concerns underscore lack of approval; avoid outside regulated trials. Mechanism (claimed): growth-factor delivery; Reality: unapproved. U.S. Food and Drug Administration

6. RMAT pathway context: FDA’s RMAT designation supports development of future cell/gene therapies, but none are approved for PPS1. Families should watch clinical trials rather than purchase unproven care. U.S. Food and Drug Administration

---

Surgeries

1. Cleft lip repair (typically in early months): closes the split, restores lip seal for feeding/speech, and improves appearance. Why: function and development. Often paired with NAM pre-op to optimize tissue positions. PubMed+1

2. Cleft palate repair (usually before speech develops): separates mouth and nose to improve speech and feeding. Why: enable normal resonance and reduce regurgitation; may still need speech therapy. ACPA

3. Popliteal pterygium release with Z-plasties and staged lengthening: carefully frees skin/web and protects nerves/vessels; may require skin grafts and splints. Why: restore knee extension and walking. PMC+1

4. Alveolar bone graft (later childhood): adds bone in the gum ridge to support tooth eruption and stabilize the arch. Why: dental function and orthodontic stability. ACPA

5. Genital/urologic procedures (e.g., orchiopexy for undescended testes): tailored to anatomy. Why: fertility/hygiene and psychosocial wellbeing. NCBI

---

Preventions

1. Early cleft-team referral (within 1 week of discharge) to stabilize feeding and map care. HealthyChildren.org

2. Breastmilk support or optimized bottle choice to maintain growth. Cochrane

3. Vaccinations and infection prevention to avoid respiratory/ear complications that affect speech/hearing. ASHA

4. Dental home by age 1 and routine oral hygiene to prevent caries around cleft/orthodontics. AAPD

5. Regular audiology checks for children with cleft palate. ASHA

6. Scar care compliance after surgeries to reduce contracture recurrence. ACPA

7. Physio home program to keep knee extension gains. Lippincott Journals

8. Nutrition planning pre/post-op to avoid poor wound healing. ACPA

9. Psychosocial support to lower procedure anxiety and improve adherence. ACPA

10. Genetic counseling for family planning, including discussion of inheritance risk. NCBI

---

When to see doctors

Newborns with cleft features should see a cleft/craniofacial team as soon as possible (often within a week) to check feeding, growth, and plan surgery timing. Seek urgent care for poor feeding/dehydration, breathing trouble, fever, or bleeding after surgery. Through childhood, seek care for speech delays, frequent ear infections, hearing concerns, knee pain/loss of extension, or wound problems. Lifelong, keep dental/orthodontic and primary-care follow-up; consider genetic counseling before pregnancy. HealthyChildren.org+1

---

What to eat and what to avoid

What to eat: nutrient-dense foods with adequate protein (eggs, fish, legumes), fruits/vegetables, and dairy or fortified alternatives for calcium and vitamin D—especially around surgeries to support healing and growth. Infants may need special bottles or expressed breastmilk with lactation support until repairs. Cochrane

What to avoid: hard/sharp foods right after oral surgery until cleared; sugary snacks/drinks that raise cavity risk around orthodontic appliances; and unproven “stem-cell” or “exosome” products marketed as cures—they are not FDA-approved for PPS1 or orthopedic contractures. FDA Access Data+1

---

FAQs

1) Is PPS1 inherited?
Yes—usually autosomal dominant IRF6 variants; each child of an affected parent has a 50% chance of inheriting the variant, but features vary widely. NCBI

2) Can PPS1 be cured with medicine?
No; care focuses on surgery, therapy, dental/speech, and ongoing team follow-up. No drug is approved to cure PPS1. NCBI

3) How is PPS1 diagnosed?
By clinical features plus IRF6 genetic testing to confirm and guide family counseling. NCBI

4) How common are clefts in PPS1?
Cleft lip and/or palate are common features of IRF6-related disorders, including PPS1. NCBI

5) What about speech problems?
Many children need speech-language therapy after palate repair to correct articulation and resonance. pubs.asha.org

6) Will my child need many surgeries?
Usually staged—lip, palate, knee web release(s), and later dental/orthodontic procedures. Plans are individualized. ACPA

7) Is hearing at risk?
Children with cleft palate have higher risk of middle-ear fluid and conductive hearing loss, so regular audiology is important. ASHA

8) Are “stem cells” a treatment?
No; unapproved regenerative products are widely marketed but not FDA-approved for PPS1. Avoid unless in a regulated clinical trial. U.S. Food and Drug Administration

9) What’s NAM and is it worth it?
Nasoalveolar molding can reduce cleft width and improve nasal shape before lip repair; evidence supports short-/mid-term benefits, though study quality varies. PubMed

10) How do we feed a newborn with a cleft?
Use squeezable bottles, upright positioning, and lactation support; some infants breastfeed with adjustments. Cochrane

11) When should dental care begin?
A dental home by age 1 is recommended, with lifelong preventive care. AAPD

12) What causes the knee web?
IRF6-pathway skin development differences lead to a persistent posterior knee web that can tether deeper tissues. NCBI

13) Is PPS1 the same as Bartsocas–Papas syndrome?
No. Bartsocas–Papas is usually autosomal recessive (often RIPK4) and more severe; PPS1 is IRF6-dominant. PubMed

14) Can supplements fix PPS1?
Supplements don’t treat PPS1, but good nutrition supports growth and wound healing. Folic acid is important for future pregnancies to reduce neural-tube defects in general. CDC

15) Where should we get care?
Seek an ACPA-approved cleft/craniofacial team and keep regular multidisciplinary follow-up through growth.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 04, 2025.

PDF Documents For This Disease Condition References